

Clinical Policy: Pulmonary Hypertension Agents, Oral and Inhaled

Reference Number: PHW.PDL.171

Effective Date: 01/01/2020

Last Review Date: 11/2025

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of PA Health and Wellness® that Oral and Inhaled Pulmonary Arterial Hypertension (PAH) Agents are **medically necessary** when the following criteria are met:

I. Requirements for Prior Authorization of Pulmonary Hypertension Agents, Oral and Inhaled

A. Prescriptions That Require Prior Authorization

All prescriptions for Pulmonary Hypertension Agents, Oral and Inhaled must be prior authorized.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a Pulmonary Hypertension Agent, Oral and Inhaled, the determination of whether the requested prescription is medically necessary will take into account whether the member:

1. One of the following:

- a. Is prescribed the Pulmonary Hypertension Agent, Oral and Inhaled for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication, excluding use to treat sexual or erectile dysfunction
- b. For the treatment of pulmonary arterial hypertension (PAH), is prescribed a Pulmonary Hypertension Agent, Oral and Inhaled that is appropriate for the member's clinical status and current peer-reviewed medical literature;

AND

2. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**

3. **One of the following:**

- a. If less than 18 years of age, is prescribed the Pulmonary Hypertension Agent,

Oral and Inhaled by or in consultation with a pediatric pulmonologist or pediatric cardiologist,

- b. If 18 years of age or older, **one** of the following:
 - i. Is prescribed the Pulmonary Hypertension Agent, Oral and Inhaled by or in consultation with a practitioner at a Pulmonary Hypertension Association-accredited center
 - ii. If unable to access a Pulmonary Hypertension Association-accredited center, is prescribed the Pulmonary Hypertension Agent, Oral and Inhaled by or in consultation with an appropriate specialist (i.e., pulmonologist, cardiologist, or rheumatologist) skilled in treating pulmonary hypertension;

AND

4. Does not have a contraindication to the prescribed drug; **AND**
5. For a diagnosis of PAH (WHO Group 1), **all** of the following:
 - a. Has chart documentation of right heart catheterization indicating **all** of the following hemodynamic values:
 - i. A mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg,
 - ii. A pulmonary capillary wedge pressure (PCWP), left atrial pressure, or left ventricular end-diastolic pressure ≤ 15 mm Hg,
 - iii. A pulmonary vascular resistance (PVR) $>$ (greater than) 3 Wood units,
 - b. For a member with idiopathic or heritable PAH, **one** of the following:
 - i. Has chart documentation of acute vasoreactivity testing
 - ii. Has a contraindication to vasoreactivity testing or is at increased risk of adverse events during acute vasoreactivity testing (e.g., presence of severe [functional class IV] symptoms, low systemic blood pressure, low cardiac index, or pulmonary veno-occlusive disease),
 - c. For a member with idiopathic or heritable PAH that demonstrates acute vasoreactivity,¹ has a documented history of therapeutic failure or a contraindication or an intolerance of calcium channel blockers (i.e., amlodipine, nifedipine, or diltiazem);

AND

6. For a diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), has

¹ A positive vasoreactivity test is defined by a decrease in the mean pulmonary artery pressure by at least 10 mmHg to reach an absolute value of 40 mmHg or less without a decrease in cardiac output.

chart documentation of right heart catheterization indicating **both** of the following hemodynamic values:

- a. A mPAP \geq 25 mmHg
- b. A pulmonary vascular resistance (PVR) > (greater than) 3 Wood units

AND

7. For a diagnosis of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), has **both** of the following:
 - a. Chart documentation of right heart catheterization indicating **all** of the following hemodynamic values:
 - i. An mPAP greater than or equal to 25 mmHg,
 - ii. A PCWP less than or equal to 15 mmHg,
 - iii. A PVR greater than 3 Wood units
 - b. Chart documentation of recent computed tomography imaging demonstrating interstitial lung disease;

AND

8. For a non-preferred Pulmonary Hypertension Agent, Oral and Inhaled, **one** of the following:
 - a. Has a history of therapeutic failure of or a contraindication or an intolerance to the preferred Pulmonary Hypertension Agents, Oral and Inhaled approved or medically accepted for the member's diagnosis or indication
 - b. Has a current history (within the past 90 days) of being prescribed the same non-preferred Pulmonary Hypertension Agent, Oral and Inhaled (does not apply to non-preferred brands when the therapeutically equivalent generic is preferred or to non-preferred generics when the therapeutically equivalent brand is preferred)

See the Preferred Drug List (PDL) for the list of preferred Pulmonary Hypertension Agents, Oral and Inhaled at: <https://papdl.com/preferred-drug-list>

AND

9. If the prescription for a Pulmonary Hypertension Agent, Oral and Inhaled is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in PA.CP.PMN.59 Quantity Limit Override.

NOTE: If the member does not meet the clinical review guidelines above but, in the professional judgement of the physician reviewer, the services are medically

necessary to meet the medical needs of the member, the request for prior authorization will be approved.

FOR RENEWALS OF PRIOR AUTHORIZATION FOR Pulmonary Hypertension Agents, Oral and Inhaled

Agents, Oral and Inhaled: The determination of medical necessity of a request for renewal of a prior authorization for a Pulmonary Hypertension Agent, Oral and Inhaled that was previously approved will take into account whether the member:

1. Continues to benefit from the requested Pulmonary Hypertension Agent, Oral and Inhaled based on the prescriber's assessment; **AND**
2. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
3. **One** of the following:
 - a. If less than 18 years of age, is prescribed the Pulmonary Hypertension Agent, Oral and Inhaled by or in consultation with a pediatric pulmonologist, pediatric cardiologist
 - b. If 18 years of age or older, **one** of the following:
 - i. Is prescribed the Pulmonary Hypertension Agent, Oral and Inhaled by or in consultation with a practitioner at a Pulmonary Hypertension Association-accredited center
 - ii. If unable to access a Pulmonary Hypertension Association-accredited center, is prescribed the Pulmonary Hypertension Agent, Oral and Inhaled by or in consultation with an appropriate specialist (i.e., pulmonologist, cardiologist, or rheumatologist);

AND

4. Does not have a contraindication to the prescribed drug; **AND**
5. For a non-preferred Pulmonary Hypertension Agent, Oral and Inhaled with a therapeutically equivalent brand or generic that is preferred on the PDL, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred therapeutically equivalent brand or generic that would not be expected to occur with the requested drug. See the Preferred Drug List (PDL) for the list of preferred Pulmonary Hypertension Agents, Oral and Inhaled at: <https://papdl.com/preferred-drug-list>
AND
6. If the prescription for a Pulmonary Hypertension Agent, Oral and Inhaled is for a quantity that exceeds the quantity limit, the determination of whether the

prescription is medically necessary will also take into account the guidelines set forth in PA.CP.PMN.59 Quantity Limit Override

NOTE: If the member does not meet the clinical review guidelines above but, in the professional judgement of the physician reviewer, the services are medically necessary to meet the medical needs of the member, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a Pulmonary Hypertension Agent, Oral and Inhaled. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member.

D. Approval Duration:

- New Request: 6 months**
- Renewal Request: 12 months**

E. References

1. Abman SH. Pediatric Pulmonary Hypertension Network: Implications of the FDA warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension: November 19, 2012.
2. Adcirca Package Insert. Indianapolis, IN: Eli Lilly and Company; September 2020.
3. Adempas Package Insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; September 2021.
4. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting Survival in Patients with Pulmonary Arterial Hypertension. *CHEST* 2019; 156(2):323-337. [DOI: 10.1016/j.chest.2019.02.004].
5. Chin KM, Gaine SP, Gerges C, Jing ZC, Mathai SC, Tamura Y, McLaughlin VV, Sitbon O. Treatment algorithm for pulmonary arterial hypertension. *Eur Respir J*. 2024 Oct 31;64(4):2401325. doi: 10.1183/13993003.01325-2024. PMID: 39209476; PMCID: PMC11525349.
6. Condon DF, Nickel NP, Anderson R, Mirza S, de Jesus Perez VA. The 6th World Symposium on Pulmonary Hypertension: what's old is new. *F1000Res*. 2019;8:F1000 Faculty Rev-888. Published 2019 Jun 19. [DOI:10.12688/f1000research.18811.1].
7. FDA Drug Safety Communication: FDA recommends against use of Revatio in children with pulmonary hypertension; September 21, 2012.
8. Fedullo PF. Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension. Muller NL, Rivera-Lebron B, Finlay G, eds. Waltham, MA: UpToDate Inc. Updated May 21, 2025. Accessed

August 25, 2025.

9. Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. *EUR Respir J* 2019; 53: 1801904 [DOI:10.1183/13993003.01904-2018].
10. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. *Eur Respir J*. 2019; 53 1801889. [DOI: 10.1183/13993003.01889-2018].
11. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *N Engl J Med*. 2013 Jul 25;369(4):319-29. doi: 10.1056/NEJMoa1209657. PMID: 23883377.
12. Hopkins W, Rubin LJ. Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy. Mandel J, Finlay G eds. Waltham, MA: UpToDate Inc. Updated July 14, 2025. Accessed August 25, 2025.
13. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. Erratum in: *Eur Heart J*. 2023 Apr 17;44(15):1312. doi: 10.1093/eurheartj/ehad005. PMID: 36017548.
14. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T, Tapson VF, Ghofrani HA, Jenkins DP. Chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2019 Jan 24;53(1):1801915. doi: 10.1183/13993003.01915-2018. PMID: 30545969; PMCID: PMC6351341.
15. Klinger, James R. et al. Therapy for Pulmonary Arterial Hypertension in Adults. *CHEST* 2019;155(3): 565-586. [DOI: 10.1016/j.chest.2018.11.030].
16. Letairis Package Insert. Foster City, CA: Gilead Sciences, Inc.; April 2025.
17. Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. *J Am Heart Assoc*. 2023 Apr 18;12(8):e029024. doi: 10.1161/JAHA.122.029024. Epub 2023 Apr 7. PMID: 37026538; PMCID: PMC10227272.
18. Mullen MP, Kulik T. Pulmonary hypertension in children: Classification, evaluation, and diagnosis. Fulton DR, Austin ED, Armsby C eds. Waltham, MA: UpToDate Inc. Updated April 16, 2025. Accessed August 25, 2025.
19. Opsumit Package Insert. Titusville, NJ: Actelion Pharmaceuticals US, Inc.; April 2025.
20. Orenitram Package Insert. Research Triangle Park, NC: United Therapeutics Corp.; August 2023.
21. Pulmonary Hypertension Association Consensus Statement; Revatio (sildenafil) for Pediatric Use: September 2012.
22. Revatio Package Insert. Morgantown, WV: Viatris Specialty LLC; January 2023.
23. Rubin LJ, Hopkins W. Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults. Mandel J, Finlay G eds. Waltham, MA: UpToDate Inc.

Updated December 11, 2024. Accessed August 25, 2025.

24. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J*. 2019;53(1):1801913. Published 2019 Jan 24. [DOI:10.1183/13993003.01913-2018].
25. Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. *Respiratory Medicine*. Volume 104, Issue 4 April 2010, Pages 481-496. [DOI: 10.1016/j.rmed.2009.11.015].
26. Tracleer Package Insert. Titusville, NJ: Actelion Pharmaceuticals US, Inc.; July 2025.
27. Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, Allen R, Feldman J, Argula R, Smith P, Rollins K, Deng C, Peterson L, Bell H, Tapson V, Nathan SD. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. *N Engl J Med*. 2021 Jan 28;384(4):325-334. doi: 10.1056/NEJMoa2008470. Epub 2021 Jan 13. PMID: 33440084.
28. Tyvaso Package Insert. Research Triangle Park, NC: United Therapeutics Corp.; May 2022.
29. Uptravi Package Insert. Titusville, NJ: Actelion Pharmaceuticals US, Inc.; July 2022.
30. Ventavis Package Insert. Titusville, NJ: Actelion Pharmaceuticals US, Inc.; March 2022.

Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020
Q3 2020 annual review: no changes.	07/2020
Q1 2021 annual review: no changes.	01/2021
Q1 2022: revised according to DHS revisions 01/03/2022	10/2021
Q1 2023 annual review: no changes.	11/2022
Q1 2024 annual review: no changes.	11/2023
Q1 2025: policy revised according to DHS revisions effective 01/06/2025.	11/2024
Q1 2026: policy revised according to DHS revisions effective 01/05/2026.	11/2025